Articles from Attovia Therapeutics, Inc.

ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions
By Attovia Therapeutics, Inc. · Via GlobeNewswire · January 23, 2025

Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer
By Attovia Therapeutics, Inc. · Via GlobeNewswire · October 15, 2024

FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization.
By Attovia Therapeutics, Inc. · Via GlobeNewswire · July 9, 2024

-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform
By Attovia Therapeutics, Inc. · Via GlobeNewswire · May 9, 2024

-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer
By Attovia Therapeutics, Inc. · Via GlobeNewswire · March 26, 2024

-- Financing supports building immunology and inflammation pipeline, advancing lead programs into the clinic and ongoing development of the Attobody platform
By Attovia Therapeutics, Inc. · Via GlobeNewswire · February 8, 2024